Global Footprint Cisbio maintains a global footprint with facilities in the United States, Japan, and China and markets its products worldwide. As part of PerkinElmer, sales and support networks can be leveraged to expand adoption of HTRF assays, immunoassays, and related services across new regions and regulated markets, accelerating international growth.

Integrated Platforms HTRF technology sits at the core of drug discovery and in vitro diagnostics. There is a clear opportunity to co-sell Cisbio’s assays with PerkinElmer instrument platforms and services to offer pharma customers an integrated, end-to-end screening and biomarker solution.

Disease Focus The portfolio focuses on cancer, metabolic, and autoimmune diseases through immunoassays. Create disease-specific bundles that combine validated panels with technical support and validation services to win research and development contracts from oncology and autoimmune disease programs.

Data Capabilities Usage of scikit-learn and Infosum indicates potential for analytics-enabled R&D and secure data collaboration. Propose data-driven assay optimization, ML-powered data analysis, and CRO partnerships to differentiate offerings and improve study outcomes.

Growth Pathways With a mid-market size and global reach, Cisbio can accelerate growth by cross-selling within PerkinElmer’s customer base and partner network. Target early-stage biotechs and CROs seeking reliable assays, scalable production, and global logistics.